FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
Savara (NASDAQ: SVRA) reported Q4 EPS of ($0.72), $0.31 worse than the analyst estimate of ($0.41).
Results from the open-label period of IMPALA reaffirm our strong belief that Molgradex could improve outcomes for patients with aPAP, a rare and debilitating lung disease, said Rob Neville, Chief Executive... More

